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The  identiﬁcation  of extensive  genetic  heterogeneity  in human  breast  carcinomas  poses  a  signiﬁcant
challenge  for  designing  effective  treatment  regimens.  Signiﬁcant  genomic  evolution  often  occurs  during
breast  cancer  progression,  creating  variability  within  primary  tumors  as well  as  between  the primary
carcinoma  and  metastases.  Current  risk  allocations  and  treatment  recommendations  for  breast  cancer
patients  are  based  largely  on  characteristics  of the  primary  tumor;  however,  genetic  differences  between
disseminated  tumor  cells  and  the  primary  carcinoma  may  negatively  impact  treatment  efﬁcacy  and
survival. In this  review  we  (1)  present  current  information  about  genomic  variability  within  primary
breast  carcinomas,  between  primary  tumors  and regional/distant  metastases,  among  circulating  tumorirculating tumor cells
ell-free DNA
cells  (CTCs)  and disseminated  tumor  cells  (DTCs),  and  in  cell-free  nucleic  acids  in circulation,  and  (2)
describe  how  this  heterogeneity  affects  clinical  care  and  outcomes  such  as  recurrence  and  therapeu-
tic  resistance.  Understanding  the  evolution  and  functional  signiﬁcance  of the  composite  breast  cancer
genome  within  each  patient  is  critical  for developing  effective  therapies  that can  overcome  obstacles
presented  by molecular  heterogeneity.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Decades of observation and research have shown that malignant
arcinomas are heterogeneous. Three main types of heterogeneity
ave been described: (1) population heterogeneity or differences
mong tumors from different patients, (2) intratumor or spatial
eterogeneity within a single tumor mass, and (3) temporal hetero-
eneity reﬂecting variability over time during tumor growth and
evelopment or in response to treatment [1]. In this review, we
ocus on intratumor heterogeneity in breast cancer, with particular
mphasis on molecular and genomic variability within carcinomas
nd among disseminated cells and cell-free nucleic acids, as well
s the effect of heterogeneity on treatment response.
. Historical perspective
Early observational studies of heterogeneity within a single car-
inoma were conducted in animals. Histological studies of mouse
ammary tumors revealed extensive variability in morphology of
ells derived from a single tumor [2]. Further research detected
he presence of distinct cell types within mammary tumors that
iffered markedly in growth properties, antigen expression, kary-
type, and sensitivity/response to therapeutic agents [3,4]. These
tudies provided some of the ﬁrst evidence that mammary carcino-
as  contain a number of distinct tumorigenic cell types that differ
t the molecular level.
In humans, early studies observed that human breast tumors
re also composed of multiple subpopulations of cells that differ
n their histologic and biochemical properties. Cytogenetic studies
etected heterogeneity in chromosomal alterations within archival
reast cancer specimens [5] and found that human breast carci-
omas exhibit intratumor differences in the expression of clinical
iomarkers, such as estrogen (ER) and progesterone (PR) recep-
ors, and the extent of human epidermal growth factor receptor 2
HER2) gene ampliﬁcation [6–8]. More recent studies have detected
ubstantial spatial heterogeneity at the genomic level in primary
reast carcinomas using comparative genomic hybridization [9]
nd genomic ﬁngerprinting [10], with different patterns of chromo-
omal changes observed in different regions of the primary tumor.
. Cancer stem cells
The idea that cancer develops from morphologically normal
ells through the accumulation of genetic changes that activate
ncogenic pathways and inactivate tumor suppressor genes is
ell-established [11]; however, the cells in which these muta-
ions originate have not been well-characterized. Normal adult
tem cells are relatively rare, largely quiescent cells that survive
n an undifferentiated state for extended periods of time and
ave the capacity for unlimited self-renewal and the ability to
enerate morphologically diverse progeny cells [12]. Over time
years to decades), stem cells are hypothesized to acquire speciﬁc
arcinogenesis-initiating mutations and become cancer stem cells.
urther mutations in pathways that alter genome stability, prolifer-
tive potential, growth inhibition, normal cellular differentiation,
nd resistance to apoptosis may  occur in more differentiated cells,
eading to substantial genetic diversiﬁcation among clonal popu-
ations of cells within the primary tumor [13,14]. The mutational
istory of stem cells from which carcinomas arise may  inﬂu-
nce heterogeneity and metastatic potential. Accordingly, tumors
erived from early stem cells may  have a greater capacity forPlease cite this article in press as: R.E. Ellsworth, et al., Molecular hete
for patient care, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016
enomic heterogeneity compared to carcinomas that arise from
ater stem-like cells [15].
In breast cancer, substantial intratumor heterogeneity for
enetic alterations and activated signaling pathways has been PRESS
lopmental Biology xxx (2016) xxx–xxx
observed among populations of putative breast cancer stem cells
[16]. The Notch, Sonic hedgehog, and Wnt  signaling pathways con-
trol cell growth, differentiation, and apoptosis in the regulation
of normal breast development, and increasing evidence indicates
that inherited or acquired mutations in one or more of these
pathways may  occur in cancer stem cells [17]. This genetic het-
erogeneity within a developing carcinoma may  lead to phenotypic
heterogeneity, which inﬂuences important clinical outcomes such
as metastatic potential and therapeutic resistance [18].
4. Evaluation of breast tumor heterogeneity by single-cell
analysis
Technological advancements for genomic analysis now permit
the assessment of copy number changes and sequence variants
at the single cell level. Next-generation sequencing of individual
cells is sufﬁcient to examine more than 90% of the genome with
∼10× average exome coverage depth per cell [19]. Because rare de
novo mutations and/or transcriptional changes in individual cells or
small populations of cells cannot be detected when analyzing larger
sections of tumors [20], “single-cell genomics” is increasingly being
used to study individual cells from primary tumors, metastases,
cancer stem cells, and circulating (CTCs) or disseminated (DTCs)
tumor cells to guide diagnosis, prognosis, and treatment.
4.1. Breast cancer cell lines
Studies focusing on breast cancer cell lines have identiﬁed
extensive cell to cell heterogeneity within a single cell line. One
study focusing on single-cell-derived sub-clones from the HCC38
breast cancer cell line found extensive copy number heterogene-
ity among individual cells that could be attributed to novel DNA
changes during cell division in genomically unstable cancer cells
[21]. Sequencing of single cells from an ER-/HER2+ cell line revealed
additional mutations not detected in bulk genomic DNA from the
same cell line and showed that no two cells had identical mutation
proﬁles [19]. Investigating the effects of heterogeneity on paclitaxel
(Taxol) resistance using single-cell RNA-sequencing (RNAseq), Lee
and colleagues [22] found signiﬁcant molecular heterogeneity
among individual cells that could not be detected in pooled cell
populations of the MDA-MB-231 metastatic breast cancer cell line.
Cell-speciﬁc RNA variants led to transcriptional heterogeneity and
survival of cells capable of developing a drug-resistant phenotype.
4.2. Primary breast tumors
One of the earliest studies performing copy number evaluation
on single cells from triple negative breast carcinomas identiﬁed
varying numbers of distinct clonal subpopulations of cells, sug-
gesting a punctuated clonal evolution of tumor growth, rather than
gradual tumor progression [23]. A novel whole-genome and whole-
exome single-cell sequencing method called Nuc-Seq showed that
no two  single cells from either luminal A or triple negative breast
carcinomas exhibited identical genomic proﬁles [24]. The single-
cell sequencing data suggest that the earliest steps of tumor
development involve copy number changes that occur in punc-
tuated bursts, but point mutations evolve gradually, generating
extensive sequence diversity that may  play an important role inrogeneity in breast cancer: State of the science and implications
/j.semcdb.2016.08.025
the development of drug resistance (Fig. 1) [25]. Knowledge gained
from single-cell studies may  improve early detection and disease
monitoring in breast cancer patients and promote the development
of precise and personalized cancer therapy [26].
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ef.  [25]. Reprinted with permission from AAAS.
. Patient derived xenografts
To improve our understanding of tumor responses to various
harmacologic agents, patient-derived breast tumor xenografts
ave been established for several breast tumor subtypes.
enografts are created by engrafting human breast tumor frag-
ents derived from surgical specimens into immunodeﬁcient mice.
enografts are believed to faithfully recapitulate the histological
omplexity and molecular heterogeneity of the primary carcinoma,
nd thus, may  serve as effective models for preclinical evaluation
f potential chemotherapeutics. By monitoring tumor responses to
arious cancer therapies, the optimum treatment regimen for the
atient can be selected [27].
Although xenograft models exhibit histopathological char-
cteristics similar to the primary carcinoma, next-generation
equencing of a primary tumor, a xenograft derived from the pri-
ary tumor, and a brain metastasis from a triple negative breast
ancer patient detected a wide range of allele frequencies for var-
ous mutations, enrichment of some de novo sequence mutations,
nd copy number variation in the metastasis and xenograft com-
ared to the primary tumor. These data suggest that considerable
enetic heterogeneity exists within the primary tumor and forma-
ion of metastases and xenografts selects for speciﬁc cells carrying
 distinct subset of mutations present in the primary tumor [28].
Human breast cancer xenografts are generally assumed to be
easonable models of the primary tumors from which they were
stablished; however, molecular heterogeneity within primary
arcinomas can inﬂuence xenograft clonal dynamics and clonal
election. Whole genome single-cell sequencing has shown that
n a minority of cases, clonal lineages observed in xenografts are
imilar to those in the primary tumor. In the majority of patients,
olecular heterogeneity among xenografts is evident, suggesting
hat preexisting rare clones from the primary tumor often expand
o dominate the xenografts [29].
. Heterogeneity between primary breast carcinomas and
etastases
.1. Regional and distant metastases
Metastasis represents an important step in the progression
f malignant breast cancer from a localized stage to an aggres-
ive systemic disease. Despite the fact that distant metastases are
esponsible for the majority of cancer-related mortality, current
isk allocations and treatment recommendations targeting breastPlease cite this article in press as: R.E. Ellsworth, et al., Molecular hete
for patient care, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016
ancer metastases are based largely on histological and molecular
haracteristics of the primary tumor [30]. However, genetic dif-
erences between metastases and the primary tumor may  affect
reatment efﬁcacy.cer patient showing extensive genetic heterogeneity at the single-cell level. From
Research on genetic differences between primary breast
carcinomas and paired locoregional metastases have shown
tremendous variation in the degree of genetic differentiation
between primary tumors and metastases within patients [31]. Phy-
logenetic analyses have shown that multiple genetically divergent
lineages of metastatic cells independently colonize the axillary
lymph nodes [32]. Using large-scale DNA sequencing [28,33]
and immunoFISH [34], researchers have observed marked single
nucleotide and copy number differences between primary breast
carcinomas and metastases.
These studies indicate that although metastases descend from
the primary tumor, substantial genetic differences attributable
to signiﬁcant genomic evolution that often occurs with disease
progression may  be evident between the primary carcinoma and
metastases. Genomic heterogeneity characteristic of metastatic
breast cancer explains why  biomarkers measured exclusively from
the primary tumor may  not be sufﬁciently informative for pre-
dicting responsiveness to therapy. To illustrate this point, the
progressive Intensive Trial of Omics in Cancer (ITOMIC) was
designed to prospectively enroll patients with triple negative breast
cancer to appropriate therapies based on the cumulative molecu-
lar proﬁle of the cancer over space (primary vs metastases) and
time (progression) [35]. Comprehensive genomic, transcriptomic,
and proteomic proﬁling were performed on multiple biopsies taken
at study outset for each ITOMIC patient, followed by multiple
biopsies at each progression and ﬁnally at autopsy. Spatial and
temporal heterogeneity in single nucleotide variants, copy num-
ber variants, chromosomal rearrangements, and insertion/deletion
polymorphisms were observed in primary carcinomas and between
metastases (Fig. 2) [36]. These molecular differences within pri-
mary disease and between metastases may  serve as the basis for
outgrowth of sub-clonal disease in response to each administered
therapy and suggest that the optimal strategy for treatment must
include in-depth genomic and proteomic proﬁles of multiple biop-
sies across space and time for each individual patient.
6.2. Circulating and disseminated tumor cells
Research on the role of CTCs found in the bloodstream and
DTCs in bone marrow of cancer patients has grown exponentially
in recent years because the dissemination of cells from a primary
carcinoma through the circulatory system is believed to be a criti-
cal step in the process of disease progression and metastasis. CTCs
are viable cancer cells that are shed from a primary carcinoma and
circulate throughout the vasculature, carrying genetic alterations
found in the primary tumor [37]. Because CTCs are believed to ini-rogeneity in breast cancer: State of the science and implications
/j.semcdb.2016.08.025
tiate growth of metastatic deposits in distant organs, the ability
to detect and quantify CTCs in peripheral blood of breast cancer
patients may  provide an easily accessible marker with high prog-
nostic and predictive value. The ability to quantify CTCs through
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cig. 2. Whole genome analysis of multiple biopsies from a 45-year-old woman  dia
eterogeneity during treatment and reveals the evolution of molecular signatures t
inimally-invasive blood collection during treatment has led to
he concept of using CTC assays as a “liquid biopsy”. Pioneer-
ng research evaluated the prevalence of CTCs in the bloodstream
f patients with metastatic disease versus healthy individuals to
etermine clinical utility. Evaluation of 422 metastatic breast can-
er patients showed that CTC count varied dramatically among
atients (84 ± 885 CTCs per 7.5 ml  of whole blood) and 26% of
atients had increased CTC counts (≥5 CTCs/7.5 ml  whole blood)
38]. Further studies have established the presence and/or abun-
ance of CTCs in whole blood as a reliable independent predictor
f poor overall survival, disease-related mortality, unfavorable
esponse to treatment, and early recurrence in numerous cancer
ypes including breast cancer [39–43].
Although presence of CTCs is strongly prognostic in patients
ith breast cancer, enumeration alone is not sufﬁcient to pre-
ict potential beneﬁts from therapy. The SWOG S0500 randomized
rial found that switching to an alternate cytotoxic therapy in
etastatic breast cancer patients whose CTC counts remained high
fter 21 days of ﬁrst-line chemotherapy did not improve overall
urvival [41]. Consequently, the American Society of Clinical Oncol-
gy (ASCO) guidelines on use of tumor markers in breast cancer
ecently concluded: (1) there is no evidence at this time that chang-
ng therapy solely on the basis of circulating biomarkers improves
ealth outcomes, quality of life, or cost effectiveness; and (2) cur-
ent data are insufﬁcient to recommend use of CTC counts alone for
onitoring response to treatment [44].
At present, ER, PR, and HER2 status are assessed in pri-
ary breast carcinomas as part of standard clinical practice;Please cite this article in press as: R.E. Ellsworth, et al., Molecular hete
for patient care, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016
owever, whole-genome sequence data suggest that DTCs arise
rom sub-clonal populations of cells in the primary tumor and
ndergo further sequence evolution after dissemination [45]. Can-
er biomarkers and genetic variation therefore may change duringd with triple-negative breast cancer demonstrates extensive spatial and temporal
ay  lead to treatment failure.
disease progression, and signiﬁcant molecular discordance with
important therapeutic implications may  develop between the pri-
mary tumor and corresponding CTCs [46,47].
In a substantial percentage of patients with early stage breast
cancer, CTCs/DTCs exhibit ampliﬁcation of the HER2 gene and
expression of the HER2 gene product independent of HER2 sta-
tus in the primary carcinoma [48]. Presence of CTCs expressing
HER2 has been associated with increased mortality risk and is
predictive of poor disease-free and overall survival. In women
with early stage HER2-negative breast cancer, traditional adju-
vant chemotherapy or tamoxifen could not completely eliminate
HER2+ CTCs, and secondary adjuvant therapy with trastuzumab
was required to eliminate chemotherapy-resistant HER2+ CTCs and
improve disease-free survival [49]. Similarly, lapatinib adminis-
tered to metastatic breast cancer patients with therapy-resistant
HER2+ CTCs signiﬁcantly decreased the number of HER2+ CTCs per
patient but did not eliminate all HER2+ CTCs or signiﬁcantly stop
disease progression. Over the course of treatment, a population of
lapatinib-resistant HER2+ and HER2- CTCs emerged that may be
associated with disease recurrence [50].
Although the efﬁcacy of changing treatment regimens based on
conﬂicting biomarker status between CTCs and the primary tumor
is currently inconclusive, clinical trials are ongoing to better char-
acterize CTCs and evaluate their suitability to predict treatment
response. The DETECT trials are evaluating therapies based on HER2
status of CTCs in patients with metastatic breast cancer and the
safety of dual HER2-targeted therapy plus traditional endocrine or
chemotherapy [51]. The TREAT-CTC trial is examining the useful-rogeneity in breast cancer: State of the science and implications
/j.semcdb.2016.08.025
ness of trastuzumab in patients with early HER2- primary breast
carcinomas who have detectable HER2+ CTCs after chemotherapy
[52].
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. Heterogeneity among CTCs
.1. Genomic heterogeneity among CTCs
One reason that CTC counts have not been clinically useful
or predicting potential beneﬁts from therapy is the considerable
olecular and functional heterogeneity observed among CTCs [53].
enomic heterogeneity, including loss of heterozygosity and DNA
ariants in the phosphatidylinositol-4,5-bisphosphate 3-kinase,
atalytic subunit alpha (PIK3CA) gene, was detected among sin-
le CTCs within individual metastatic breast cancer patients [54].
ingle cell analyses have detected differences in mutation pat-
erns in the PIK3CA gene among CTCs from blood and disseminated
umor cells in tissues, and have observed changes in the mutational
tatus in CTCs with disease progression [55,56]. Further studies
sing next-generation sequencing of 50 cancer-related genes in
ultiple CTCs from ER+/HER2- and triple negative breast tumors
ound signiﬁcant genomic heterogeneity between CTCs and the
atched primary tumor, as well as extensive heterogeneity among
TCs from the same patient [57]. These data suggest that assessing
he genomic signatures of many circulating cancer cells via liq-
id biopsy in all cancer patients may  be more informative than
raditional biopsies of the primary tumor for designing targeted
herapies and monitoring therapeutic response.
Studies examining gene and protein expression in single or
ooled CTCs have found marked heterogeneity in the expression
f known tumor biomarkers, even when comparing CTCs from a
ingle venipuncture [58]. Considerable intra-patient heterogene-
ty in ER status was detected among CTCs in metastatic breast
ancer patients with ER-positive primary tumors [59]. Gene expres-
ion proﬁling has detected heterogeneity in the expression of
umerous genes among individual CTCs [60]. In situ hybridization
nd immunoﬂuorescence analyses have detected a heterogeneous
attern of expression for miR-10b, a microRNA known to be upreg-
lated in many cancers, within individual CTCs from breast cancer
atients [61]. These studies suggest that overall tumor burden may
e more thoroughly quantiﬁed by examining multiple CTCs/DTCs in
ach patient due to the vast heterogeneity among individual cells.
s heterogeneity among circulating and disseminated tumor cells
ay  be one mechanism by which patients become refractory to
ndocrine therapy, analysis of many circulating and disseminated
umor cells may  provide important clinical information for improv-
ng treatment decisions. However, at present, determining which
TCs are clinically important and the number of CTCs that should
e examined to provide clinically actionable information is largely
nknown.
Beyond the value of CTC counts for predicting survival and
ecurrence, functional characteristics of CTCs are now being iden-
iﬁed to tailor therapy and monitor disease progression. To better
redict development of resistance to therapy in metastatic breast
ancer patients, Paoletti and colleagues are evaluating combining
TC counts with protein expression assays of the ER, HER2, B-cell
ymphoma 2 (BCL-2), and Ki-67 in individual CTCs. The resulting
TC-Endocrine Therapy Index is designed to provide a more com-
rehensive view of tumor heterogeneity within individual patients
nd may  accommodate molecular heterogeneity that evolves dur-
ng treatment [62].
Most studies of CTCs in peripheral blood and/or DTCs in bone
arrow have focused on the prognostic signiﬁcance of CTC/DTC
urden, but recent reports show that molecular characterization of
hese cells is pivotal to optimizing therapeutic regimens. Overall
enomic complexity and speciﬁc driver mutations present in dis-Please cite this article in press as: R.E. Ellsworth, et al., Molecular hete
for patient care, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016
eminated cells may  be an important factor in treatment failure;
herefore, assessing the genomic signatures of many circulating
ancer cells in all patients may  be more informative than traditional PRESS
lopmental Biology xxx (2016) xxx–xxx 5
biopsies of the primary tumor for designing targeted therapies and
monitoring therapeutic response.
7.2. Epithelial-mesenchymal transition in CTCs
The epithelial-mesenchymal transition (EMT) is a process by
which epithelial cells undergo biochemical changes causing them
to lose their cellular polarity and cell-cell adhesiveness, hence
acquiring properties commonly observed in mesenchymal cells,
such as motility, invasiveness, and resistance to apoptosis. EMT  is
important in the progression of epithelial cancers such as breast
cancer and may  be induced by a diverse array of cytokines and
growth factors. Cells that disseminate from the primary carcinoma
undergo aberrant activation of EMT, thereby losing their epithelial
characteristics and acquiring more mesenchymal-like phenotypes
[63]. CTCs isolated from breast cancer patients show extensive
variability in the expression of epithelial cell adhesion molecule
(EpCAM) and other epithelial markers, and patients with metastatic
breast cancer may  carry several populations of CTCs deﬁned by
the presence of epithelial markers, mesenchymal markers, or co-
expression of epithelial and mesenchymal markers. Analysis of
CTCs captured from whole blood of breast cancer patients deﬁned
ﬁve categories of cells with exclusively epithelial, intermediate,
and exclusively mesenchymal characteristics [64]. The fraction of
CTCs co-expressing epithelial and mesenchymal markers has been
signiﬁcantly associated with poorer progression-free and overall
survival [65].
EMT  in CTCs and DTCs adds to the already complex heterogene-
ity of these disseminated cells and may  complicate their use for
outcome prediction [66]. CTCs that are in the process of EMT  or
have transitioned to a mesenchymal cell phenotype may  provide
important information regarding tumor progression and metas-
tasis, but current CTC-enrichment technologies that speciﬁcally
target epithelial markers to differentiate CTCs from other cell types
may  underestimate the number of CTCs and potentially miss critical
subpopulations of cells that are undergoing or have completed EMT
[67]. As current methods do not completely detect the heteroge-
neous population of CTCs, new technologies are needed to improve
the detection and isolation of CTCs with mesenchymal character-
istics. The cell-surface protein vimentin has shown promise for
detecting epithelial-mesenchymal transitioned CTCs in the blood
of patients with epithelial cancers [68]. Similarly, the melanoma
cell adhesion molecule (MCAM), which when combined with tra-
ditional EpCAM enrichment, signiﬁcantly improved detection of
CTCs in breast cancer patients undergoing neoadjuvant chemother-
apy compared to EpCAM alone [69]. These studies demonstrate the
potential importance of detecting cells with mesenchymal features,
which likely represent clinically relevant subpopulations of CTCs,
as part of a comprehensive liquid biopsy.
8. Cell-free DNA
Cell-free DNA (cfDNA) is composed of nucleic acid fragments
released from cells during apoptosis, necrosis, and macrophage
phagocytosis that are found in the blood stream and other bodily
ﬂuids. Although cfDNA can be identiﬁed in healthy individuals, can-
cer patients tend to exhibit higher levels of cfDNA, with signiﬁcantly
higher cfDNA concentrations observed in serum of patients with
metastatic disease (209 ± 39 ng/ml) compared to non-metastatic
patients (100 ± 30 ng/ml, p < 0.02) [70]. A portion of the cfDNA,
termed circulating tumor DNA (ctDNA), is far more abundant inrogeneity in breast cancer: State of the science and implications
/j.semcdb.2016.08.025
the bloodstream than CTCs and is rapidly cleared from the circula-
tion within hours. In addition, ctDNA proﬁles in metastatic breast
cancer patients accurately reﬂect the mutational composition of
individual CTCs [71].
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Recent years have seen growing enthusiasm for developing
linical applications for ctDNA. Methods have been developed to
uantify levels of ctDNA in the circulation and conduct genomic
nalysis of tumor-speciﬁc mutations in circulating DNA. Primary
reast carcinomas usually contain a mixture of clonal populations
f cells, which in part, account for the intratumor genetic hetero-
eneity discussed above. During disease progression, tumor DNA
ay  be released from these genetically-unique subpopulations of
ells, contributing to sequence heterogeneity in ctDNA. Studies
ave shown concordance between the mutation status of PIK3CA
ene mutations in matched primary tumor and plasma-derived cir-
ulating DNA from breast cancer patients [72,73]; however, recent
tudies using next-generation sequencing of circulating ctDNA
ave identiﬁed genomic heterogeneity with potentially impor-
ant clinical consequences between primary carcinomas and ctDNA
74].
Investigating ctDNA by monthly sampling of plasma in patients
ith various cancer types who had completed two  courses of tar-
eted therapy identiﬁed variability at baseline among patients in
he pattern of mutations in ctDNA, with TP53, PIK3CA, and KRAS
eing the most mutated genes [75]. Continued monitoring of ctDNA
uggested different clinical responses in these patients may  be
ttributable to novel genetic variation that arises among clonal pop-
lations of tumor cells during therapy. Similarly, targeted amplicon
equencing of an ER+/HER2+ primary breast carcinoma, multiple
etastatic deposits, and plasma samples collected during ∼3 years
f targeted therapy in a 42-year-old woman revealed mutational
eterogeneity that correlated with different treatment responses
cross metastases [76]. In a patient with ER+/HER2- breast can-
er that had metastasized to the liver, patterns of mutations in
rchival primary tumor DNA, synchronous liver metastasis DNA,
nd ctDNA collected from plasma at various time points were eval-
ated using massively parallel sequencing of 300 cancer-related
enes known to harbor actionable mutations [77]. Sixteen somatic
on-synonymous mutations were identiﬁed in the liver metastasis,
f which, only nine were detected in the primary tumor. However,
ll mutations present in the primary tumor and/or liver metastasis
ere captured in the ctDNA. Mutant allele frequencies in ctDNA
aried over the course of treatment and mirrored response to tar-
eted therapy.
Overall ctDNA levels in plasma correlate well with changes in
umor burden, and thus, may  prove to be a valuable tool for moni-
oring breast cancer progression [78] and for real-time, noninvasive
ampling of treatment response in women with metastatic breast
ancer [79]. Sequencing of serial plasma samples has been used
uccessfully to track genomic evolution of metastatic breast can-
er in response to therapy [80]. Over the course of treatment,
ncreased frequencies of mutations in important genes, such as
IK3CA, mediator complex subunit 1 (MED1), and growth arrest-
peciﬁc 6 (GAS6), which are associated with emergence of therapy
esistance, have been identiﬁed in cfDNA.
These studies suggest that ctDNA may  provide a more com-
lete picture of the mutational landscape of metastatic disease
nd early molecular response to treatment than CTCs or invasive
iopsies. Next-generation targeted sequencing of plasma-derived
tDNA constitutes a potentially important tool for detecting de
ovo driver mutations that occur during cancer progression, mon-
toring changes in the frequency of genetic alterations during the
ourse of targeted therapy, and identifying mutations associated
ith acquired drug resistance in patients with advanced disease
81]. Other potential applications include detecting residual dis-
ase following chemotherapy, noninvasive tumor genotyping, andPlease cite this article in press as: R.E. Ellsworth, et al., Molecular hete
for patient care, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016
arly detection of cancer recurrence. At present, use of ctDNA has
ot been validated for routine clinical use in breast cancer patients
nd additional research is ongoing to identify diagnostic and prog- PRESS
lopmental Biology xxx (2016) xxx–xxx
nostic uses of ctDNA that overcome the complexities posed by
intra-tumor genetic heterogeneity.
9. Clinical implications
In clinical practice, a single tumor biopsy is likely to contain
only a minority of genetic aberrations present in the entire carci-
noma, which leads to an underestimation of the mutational burden
of heterogeneous tumors [10] and inaccurate prediction of appro-
priate therapy [82]. Currently, breast cancer patients rarely receive
a metastatic site biopsy; however, biopsies of metastatic deposits
may become a clinical necessity for all patients to ensure thera-
pies effectively target genomic heterogeneity between the primary
carcinoma and metastases [83]. Although discordance in receptor
status between primary and metastatic lesions may  lead to detri-
mental outcomes, if clinicians alter patient management based on
results of a metastatic biopsy, discordance is no longer associated
with detrimental effects on outcome [84].
In addition to metastatic deposits, routine serial monitoring
of breast cancer heterogeneity during disease progression or in
response to treatment in CTCs, DTCs, and/or ctDNA shows great
promise for overcoming sampling bias when only a limited num-
ber of biopsies are available from the primary tumor or metastases.
However, ctDNA studies have not been established in the clinical
environment and many insurance companies do not cover mul-
tiple molecular tests on liquid biopsies throughout the course of
treatment.
Many traditional cancer therapeutics have been developed
to target rapidly proliferating cells that comprise the bulk of
the primary tumor [85]. These agents usually produce clinically
encouraging results in initial phases of treatment, exempliﬁed by
impressive decreases in the size of the primary tumor; however,
clinical remission is often temporary as relatively quiescent, and
possibly genetically diverse, cancer stem cells may survive and lead
to recurrence once therapy is completed. Although the choice of
targeted therapy is often based on mutations present in an ini-
tial biopsy specimen, these “actionable” mutations may no longer
drive disease progression once tumor cells disseminate from the
primary carcinoma. Likewise, the predominant clone(s) in the pri-
mary tumor may not be prevalent in the metastases or CTCs due to
clonal selection that occurs with certain therapies. Thus, it is vitally
important to identify which clone(s) within a cancer patient is(are)
the most biologically relevant to disease progression or therapeutic
resistance [86].
Radically new practices for optimal clinical management of
breast cancer patients are urgently needed, but identiﬁcation and
implementation of such strategies will be challenging. Large clin-
ical trials must assess the value of matching patients to speciﬁc
interventions or targeted therapies based on genetic proﬁling and
determine if comprehensive genomic characterization and serial
monitoring meaningfully improve patient care [87]. If multiple clin-
ically actionable variants are present, a consistent framework must
be developed for interpreting complex genomic results and prior-
itizing treatments. Other areas of investigation that are needed to
improve patient outcomes include: (1) selecting combinations of
agents that appropriately target driver mutations; (2) determining
how best to deal with deleterious (passenger) mutations that may
not be the primary drivers of carcinogenesis or metastases; and (3)
fully exploiting the promise of immunotherapy [88].
10. Conclusionsrogeneity in breast cancer: State of the science and implications
/j.semcdb.2016.08.025
Extensive intraindividual genetic heterogeneity has been iden-
tiﬁed in breast cancer patients, from primary carcinomas to
metastases to disseminated cancer cells and cell-free DNA. This
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eterogeneity is dynamic and evolves unpredictably during disease
rogression, creating signiﬁcant challenges for modern chemother-
peutics [89]. The extent of heterogeneity in breast cancer will
ikely necessitate a paradigm shift from standard pathological clas-
iﬁcations of breast carcinomas to a more personalized approach
n which heterogeneity is thoroughly characterized prior to treat-
ent [90]. Recent advances in DNA sequencing technologies have
een useful for identifying genomic heterogeneity among sub-
lonal populations of tumor cells, but the extent of genomic (and
ranscriptional) heterogeneity at the individual cell level within
rimary breast tumors and metastases remains largely unknown.
arge scale clinical trials encompassing various stages of breast can-
er will be needed to determine the clinical value of spatial and
emporal variation in the genomic landscape of breast cancer for
uiding treatment.
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